DRAP seizes poisonous solvent used in cough syrup

Drugs authority seizes toxic propylene glycol, linked to child deaths; recall issued, investigation underway


Reuters January 11, 2024
It was not clear whether any amount of the imported chemical was used in local cough syrup. PHOTO: CREATIVE COMMONS

ISLAMABAD:

The Drug Regulatory Authority of Pakistan (DRAP) said on Thursday that it has seized a batch of contaminated propylene glycol solvent that was labelled as manufactured by Dow Chemical, Thailand.

Dow Chemical, Thailand did not respond to a request for a comment.

The move comes as authorities have identified toxic propylene glycol used in cough syrups as a possible reason for the deaths of more than 300 children in Indonesia, Gambia and Uzbekistan since 2022.

The World Health Organization has linked the deaths outside Indonesia to cough syrups made in India.

"The Regulatory field force has taken possession of a contaminated batch of Propylene Glycol and is investigating the entire supply chain of this batch," DRAP said in an alert, ordering the recall from local and export markets of any products manufactured from the same batch of propylene glycol.

Read also: WHO identifies India-made contaminated cough syrup in Western Pacific

"The batch was labelled as manufactured by Dow Chemical, Thailand," it said.

"On analysis of a sample by the Central Drug Laboratory in Karachi, an unacceptable level of Ethylene Glycol was found," which can lead to serious health risks, the drug authority said.

It said the Ethylene Glycol's ingestion can "affect the central nervous system, and heart, and can cause kidney damage, which can be fatal."

It was not clear whether any amount of the imported chemical was used in local cough syrup.

The drug authority has directed that finished products manufactured from any other batch of propylene glycol from Dow Chemical Thailand to be put on hold.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ